Accenture vs Johnson & Johnson: Revenue, Profit and Business Model
Accenture reported $69.7B of revenue in FY2025 and $7.7B of net income. Johnson & Johnson reported $94.2B of revenue in FY2025 and $26.8B of net income.
Latest financial snapshot
Accenture
- Latest revenue
- $69.7B (FY2025)
- Net income
- $7.7B
- Net margin
- 11.0%
- Revenue growth
- +8.0% a year, FY2016–FY2025
Johnson & Johnson
- Latest revenue
- $94.2B (FY2025)
- Net income
- $26.8B
- Net margin
- 28.5%
- Revenue growth
- +3.0% a year, FY2016–FY2025
Financial summary
Accenture
Accenture's fiscal year ends August 31. Revenue rose from $34.80B in FY2016 to $69.67B in FY2025, and net income attributable to Accenture plc rose from $4.11B to $7.68B over the same period. FY2025 brought $80.62B in new bookings, $10.87B of free cash flow, GAAP diluted EPS of $12.15 and $8.3B returned to shareholders through dividends and buybacks. Spending on acquisitions was $6.58B in FY2024 and $1.47B in FY2025. In Q3 FY2026 (to May 31, 2026) revenue was $18.72B, up 6% in U.S. dollars and 3% in local currency, and full-year FY2026 results are due on October 1, 2026.
Johnson & Johnson
J&J's sales grew from $85.2 billion in 2023 to $88.8 billion in 2024 and $94.2 billion in 2025, while FY2025 net earnings reached $26.8 billion. Q2 2026 sales were $25.31 billion (Innovative Medicine $16.38 billion, MedTech $8.93 billion), net earnings were $5.53 billion, adjusted EPS was $2.90, and first-half free cash flow was about $8.7 billion. Management guides 2026 sales of $100.8 to $101.4 billion and adjusted EPS of $11.60 to $11.75. The company has raised its dividend for more than 60 consecutive years, and its market value was roughly $644 billion in mid-September 2026.
Revenue and profit by year
Accenture
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2025 | $69.7B | $7.7B | 11.0% | +7.4% | Source |
| FY2024 | $64.9B | $7.3B | 11.2% | +1.2% | Source |
| FY2023 | $64.1B | $6.9B | 10.7% | +4.1% | Source |
| FY2022 | $61.6B | $6.9B | 11.2% | +21.9% | Source |
| FY2021 | $50.5B | $5.9B | 11.7% | +14.0% | Source |
| FY2020 | $44.3B | $5.1B | 11.5% | +2.6% | Source |
| FY2019 | $43.2B | $4.8B | 11.1% | +5.4% | Source |
| FY2018 | $41B | $4.1B | 9.9% | +13.3% | Source |
| FY2017 | $36.2B | $3.4B | 9.5% | +4.0% | Source |
| FY2016 | $34.8B | $4.1B | 11.8% | — | Source |
Johnson & Johnson
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2025 | $94.2B | $26.8B | 28.5% | +6.0% | Source |
| FY2024 | $88.8B | $14.1B | 15.8% | +4.3% | Source |
| FY2023 | $85.2B | $35.2B | 41.3% | +6.5% | Source |
| FY2022 | $80B | $17.9B | 22.4% | +1.6% | Source |
| FY2021 | $78.7B | $20.9B | 26.5% | -4.7% | Source |
| FY2020 | $82.6B | $14.7B | 17.8% | +0.6% | Source |
| FY2019 | $82.1B | $15.1B | 18.4% | +0.6% | Source |
| FY2018 | $81.6B | $15.3B | 18.8% | +6.7% | Source |
| FY2017 | $76.5B | $1.3B | 1.7% | +6.3% | Source |
| FY2016 | $71.9B | $16.5B | 23.0% | — | Source |
Where the revenue comes from
Accenture
- Consulting
$35.11B in FY2025 revenue
Consulting includes strategy, technology consulting, systems integration, cloud migration, data and AI programs, and large transformation projects.
- Managed Services
$34.57B in FY2025 revenue
Managed Services includes application management, infrastructure operations, business process services, finance operations, customer operations, and other long-term outsourced work.
- AI, Data, and Digital Core
Reported across consulting and managed services
Accenture embeds AI, data, cybersecurity, cloud, enterprise platforms, and digital core modernization into client transformation programs.
- Song, Supply Chain, Engineering, and Talent
Reported across service lines
These capabilities cover customer experience, commerce, design, marketing technology, product engineering, supply chain, workforce transformation, and change management.
Johnson & Johnson
- Innovative Medicine~64%
Innovative Medicine generated $60.401 billion in FY2025 sales across oncology, immunology, neuroscience, pulmonary hypertension, infectious disease, and cardiovascular/metabolism.
- MedTech~36%
MedTech generated $33.792 billion in FY2025 sales across surgery, orthopaedics, cardiovascular, and vision products.
Business model and strategy
Accenture
How it makes money
Accenture sells professional services to large companies and governments. Consulting revenue ($35.11B in FY2025) comes from strategy, technology implementation, cloud migration and data and AI projects. Managed services revenue ($34.57B) comes from multi-year contracts to run applications, infrastructure and business processes such as finance or customer operations.
Growth strategy
Accenture grows through a mix of organic services and frequent acquisitions. It spent $6.58B on businesses and investments in FY2024 and $1.47B in FY2025, and in 2026 announced its largest recent deals: Faculty in the UK and the $1.2B Ookla agreement.
Competitive advantage
Accenture can take a client from strategy work through systems implementation and then run the resulting systems or processes under multi-year managed services contracts; in FY2025 managed services was $34.57B of its $69.67B revenue.
Johnson & Johnson
How it makes money
J&J makes money in two ways. Innovative Medicine (about 64% of FY2025 sales, $60.4 billion) sells patented prescription medicines to wholesalers, specialty pharmacies, hospitals, and governments; key products include DARZALEX for multiple myeloma, TREMFYA and STELARA in immunology, ERLEADA in prostate cancer, CARVYKTI cell therapy, and CAPLYTA, added through the 2025 Intra-Cellular Therapies deal.
Growth strategy
J&J is narrowing its portfolio toward higher-growth areas. It spun off consumer health as Kenvue in 2023, announced in October 2025 that it will separate its orthopaedics business as DePuy Synthes, and used acquisitions to refill its pipeline: Abiomed ($16.6 billion, 2022), Shockwave Medical ($13.1 billion, 2024), and Intra-Cellular Therapies ($14.6 billion, 2025).
Competitive advantage
J&J's edge is breadth plus balance-sheet strength. It runs one of the largest pharmaceutical R&D budgets in the industry, holds a AAA credit rating from S&P (one of only two US companies with that rating, alongside Microsoft), and sells into hospitals across pharmaceuticals and devices at the same time.
Questions about Accenture vs Johnson & Johnson
Which company has higher revenue — Accenture PLC or Johnson & Johnson?
Accenture PLC reported $69.7B (FY2025), while Johnson & Johnson reported $94.2B (FY2025). By last reported revenue, Johnson & Johnson is the larger business, with Accenture PLC reporting a smaller revenue base.
What is the market cap of Accenture PLC vs Johnson & Johnson?
Accenture PLC's market capitalisation stands at $110.7B, while Johnson & Johnson's is $643.9B. Johnson & Johnson carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to Accenture PLC.
Which is more financially efficient — Accenture PLC or Johnson & Johnson?
Accenture PLC generates $87k / employee in revenue per employee, while Johnson & Johnson generates $669k / employee. Johnson & Johnson shows higher revenue efficiency per headcount, though this reflects business model differences — capital-light software companies routinely outperform labour-intensive manufacturers on this metric.
How do Accenture PLC and Johnson & Johnson make money?
Accenture PLC and Johnson & Johnson generate revenue in fundamentally different ways. Accenture PLC: Accenture sells professional services to large companies and governments. Johnson & Johnson: J&J makes money in two ways.
Which company is valued higher relative to revenue — Accenture PLC or Johnson & Johnson?
On a price-to-sales (P/S) basis, Accenture PLC trades at 1.6x P/S and Johnson & Johnson at 6.8x P/S. Johnson & Johnson commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to Accenture PLC. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.
Is Accenture PLC bigger than Johnson & Johnson?
By last reported revenue, Johnson & Johnson ($94.2B (FY2025)) is the larger company compared to Accenture PLC ($69.7B (FY2025)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Accenture vs Johnson & Johnson overview